Beta
Atorvastatin
medicationStatin medication (brand name: Lipitor) for lowering cholesterol. Generic and widely prescribed.
Reported Benefits
An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor.
Not specified in source
A comprehensive safety analysis pooling data from 21 completed and 23 ongoing clinical trials involving 4,271 patients (1,845 patient-years of exposure) found that persistent transaminase elevations greater than 3 times the upper limit of normal occurred in 0.7% of patients treated with atorvastatin at dosages of 10-80 mg/day.
New Study Sheds Light on Long-Term Effectiveness and Safety of Two Widely Used Statins
Researchers in Korea
The LODESTAR clinical trial involving 4,400 adults (average age 65 years) with coronary artery disease compared rosuvastatin and atorvastatin over 3 years, finding no significant differences between the two statins for all-cause death, heart attack, stroke, or revascularization rates.
An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor.
Not specified in source
A comprehensive safety analysis pooling data from 21 completed and 23 ongoing clinical trials involving 4,271 patients (1,845 patient-years of exposure) found that persistent transaminase elevations greater than 3 times the upper limit of normal occurred in 0.7% of patients treated with atorvastatin at dosages of 10-80 mg/day.
Reported Side Effects
Short-Term Atorvastatin Therapy in Healthy Individuals Results in Lower Cholesterol but Elevated Plasma Enzymes
Not specified in source
A 4-week study of 21 healthy individuals aged 25-63 receiving moderate-dose atorvastatin (20 mg/day) demonstrated significant reductions in total cholesterol, LDL-cholesterol, non-HDL-cholesterol, and triglycerides, but also showed elevated plasma liver enzymes (AST, ALT, CK, LDH) and no significant effects on matrix metalloproteinase levels.
An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor.
Not specified in source
A comprehensive safety analysis pooling data from 21 completed and 23 ongoing clinical trials involving 4,271 patients (1,845 patient-years of exposure) found that persistent transaminase elevations greater than 3 times the upper limit of normal occurred in 0.7% of patients treated with atorvastatin at dosages of 10-80 mg/day.
An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor.
Not specified in source
A comprehensive safety analysis pooling data from 21 completed and 23 ongoing clinical trials involving 4,271 patients (1,845 patient-years of exposure) found that persistent transaminase elevations greater than 3 times the upper limit of normal occurred in 0.7% of patients treated with atorvastatin at dosages of 10-80 mg/day.
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
Elevated LDL cholesterol or total cholesterol levels
Short-Term Atorvastatin Therapy in Healthy Individuals Results in Lower Cholesterol but Elevated Plasma Enzymes
Not specified in source
A 4-week study of 21 healthy individuals aged 25-63 receiving moderate-dose atorvastatin (20 mg/day) demonstrated significant reductions in total cholesterol, LDL-cholesterol, non-HDL-cholesterol, and triglycerides, but also showed elevated plasma liver enzymes (AST, ALT, CK, LDH) and no significant effects on matrix metalloproteinase levels.
An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor.
Not specified in source
A comprehensive safety analysis pooling data from 21 completed and 23 ongoing clinical trials involving 4,271 patients (1,845 patient-years of exposure) found that persistent transaminase elevations greater than 3 times the upper limit of normal occurred in 0.7% of patients treated with atorvastatin at dosages of 10-80 mg/day.
Research (3 studies)
Community updates
No updates yet for this supplement.
Be the first to share your experience!